PriceTargets.com logo

Climb Bio - CLYM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.78
  • Forecasted Upside: 88.30%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 3 Strong Buy Ratings
$8.91 As of 05/1/2026 05:00 PM ET
▲ +0.03 (0.34%)

This chart shows the closing price for CLYM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Climb Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLYM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLYM

Analyst Price Target is $16.78
▲ +88.30% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Climb Bio in the last 3 months. The average price target is $16.78, with a high forecast of $26.00 and a low forecast of $8.00. The average price target represents a 88.30% upside from the last price of $8.91.

This chart shows the closing price for CLYM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 12 investment analysts is to buy stock in Climb Bio. This rating has held steady since March 2026, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 2 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026
  • 3 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/3/2026
  • 3 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/3/2026

Latest Recommendations

  • 3 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/21/2026OppenheimerBoost TargetOutperform ➝ Outperform$10.00 ➝ $18.00
4/20/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
4/15/2026MizuhoInitiated CoverageOutperform$18.00
4/15/2026MizuhoInitiated CoverageOutperform$18.00
4/8/2026BTIG ResearchReiterated RatingBuy ➝ Buy$8.00
3/24/2026B. Riley FinancialInitiated CoverageBuy$26.00
3/23/2026B. Riley FinancialUpgradeStrong-Buy
3/17/2026Truist FinancialInitiated CoverageBuy$17.00
3/17/2026Truist FinancialUpgradeStrong-Buy
3/10/2026Raymond James FinancialInitiated CoverageStrong-Buy$25.00
3/10/2026HC WainwrightBoost TargetBuy ➝ Buy$11.00 ➝ $15.00
3/6/2026Robert W. BairdBoost TargetOutperform ➝ Outperform$9.00 ➝ $12.00
3/5/2026WedbushInitiated CoverageOutperform ➝ Outperform$12.00
2/13/2026Piper SandlerInitiated CoverageOverweight
1/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/18/2025HC WainwrightBoost TargetBuy ➝ Buy$9.00 ➝ $11.00
10/16/2025BTIG ResearchReiterated RatingBuy ➝ Buy$8.00
10/16/2025William BlairInitiated CoverageOutperform
10/13/2025HC WainwrightInitiated CoverageBuy$9.00
10/13/2025HC WainwrightInitiated CoverageBuy$9.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/30/2025BTIG ResearchBoost TargetBuy ➝ Buy$7.00 ➝ $8.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/22/2025BTIG ResearchReiterated RatingBuy ➝ Buy$7.00
8/15/2025Robert W. BairdUpgradeStrong-Buy
8/15/2025Robert W. BairdInitiated CoverageOutperform$9.00
6/6/2025OppenheimerInitiated CoverageOutperform$10.00
5/22/2025BTIG ResearchInitiated CoverageBuy
5/22/2025BTIG ResearchUpgradeStrong-Buy$7.00
12/2/2024Leerink PartnersUpgradeStrong-Buy
12/2/2024Leerink PartnersInitiated CoverageOutperform$10.00
(Data available from 5/3/2021 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2026
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 6 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2026

Current Sentiment

  • 6 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Climb Bio logo
Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.
Read More

Today's Range

Now: $8.91
Low: $7.91
High: $9.10

50 Day Range

MA: $7.55
Low: $5.63
High: $9.52

52 Week Range

Now: $8.91
Low: $1.13
High: $10.10

Volume

1,790,926 shs

Average Volume

704,451 shs

Market Capitalization

$425.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.02

Frequently Asked Questions

What sell-side analysts currently cover shares of Climb Bio?

The following Wall Street sell-side analysts have issued research reports on Climb Bio in the last twelve months: B. Riley Financial, Inc., BTIG Research, HC Wainwright, Mizuho, Oppenheimer Holdings, Inc., Piper Sandler, Raymond James Financial, Inc., Robert W. Baird, Truist Financial Corporation, Wall Street Zen, Wedbush, Weiss Ratings, and William Blair.
View the latest analyst ratings for CLYM.

What is the current price target for Climb Bio?

0 Wall Street analysts have set twelve-month price targets for Climb Bio in the last year. Their average twelve-month price target is $16.78, suggesting a possible upside of 88.3%. B. Riley Financial, Inc. has the highest price target set, predicting CLYM will reach $26.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $8.00 for Climb Bio in the next year.
View the latest price targets for CLYM.

What is the current consensus analyst rating for Climb Bio?

Climb Bio currently has 1 sell rating, 8 buy ratings and 3 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CLYM will outperform the market and that investors should add to their positions of Climb Bio.
View the latest ratings for CLYM.

What other companies compete with Climb Bio?

Other companies that are similar to Climb Bio include Ardelyx, Syndax Pharmaceuticals, Generate Biomedicines, Agios Pharmaceuticals and Rapport Therapeutics. Learn More about companies similar to Climb Bio.

How do I contact Climb Bio's investor relations team?

Climb Bio's physical mailing address is 20 William Street Suite 145, Wellesley Hills MA, 02481. The company's listed phone number is 866-857-2596 and its investor relations email address is [email protected]. The official website for Climb Bio is climbbio.com. Learn More about contacing Climb Bio investor relations.